Comparing Alvotech (ALVO) & Its Peers

Alvotech (NASDAQ:ALVO – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Alvotech to similar businesses based on the strength of its earnings, dividends, institutional ownership, valuation, profitability, risk and analyst recommendations.

Profitability

This table compares Alvotech and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alvotech -50.62% N/A -11.71%
Alvotech Competitors -12,516.26% -215.91% -31.70%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Alvotech and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alvotech 2 0 5 0 2.43
Alvotech Competitors 9920 15331 45734 1601 2.54

Alvotech currently has a consensus target price of $8.40, suggesting a potential upside of 84.57%. As a group, “Biotechnology” companies have a potential upside of 107.06%. Given Alvotech’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Alvotech has less favorable growth aspects than its rivals.

Volatility & Risk

Alvotech has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500. Comparatively, Alvotech’s rivals have a beta of -1.85, suggesting that their average stock price is 285% less volatile than the S&P 500.

Insider and Institutional Ownership

47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 0.5% of Alvotech shares are owned by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Alvotech and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Alvotech $489.61 million $27.92 million -5.55
Alvotech Competitors $750.45 million $11.26 million -18.51

Alvotech’s rivals have higher revenue, but lower earnings than Alvotech. Alvotech is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Alvotech beats its rivals on 7 of the 13 factors compared.

About Alvotech

(Get Free Report)

Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.

Receive News & Ratings for Alvotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alvotech and related companies with MarketBeat.com's FREE daily email newsletter.